NCT03996850Active, not recruiting
SPECT/CT for the Characterization of Renal Masses
SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making
Source: ClinicalTrials.gov · Last updated 13 Mar 2026
Brief summary (registry, in English)
This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 102 (actual)
- First submitted
- 21 Jun 2019
- Start date
- 7 Dec 2018
- Primary completion date
- 3 Mar 2025
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Diseases
- Kidney cancer
- NCT number
- NCT03996850
What you commit to
- Study type: Observational
- Participants enrolled: 102
- From 7 Dec 2018 to the primary completion date, 3 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A prior needle biopsy of the mass resulting in histologic diagnosis.
- A prior diagnosis of kidney cancer.
- Prior surgery or radiation therapy to the kidney.
Other illness
- Presence of an active, untreated, non-renal malignancy.
- History of bleeding diathesis or recent bleeding episode.
Other
- Presence of multiple solid renal tumors.
- Unwillingness to fill out questionnaires.
Who the study is looking for
- Performance status Eastern Cooperative Oncology Group (ECOG) \< 2.
- Life expectancy (\> 1 year).
- New diagnosis of a renal tumor (within past 3 months).
- Measurable, predominantly (\> 80%) solid renal neoplasm between 1.5-5.0 cm.
- Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI).
- No definitive evidence of metastatic disease.
- Does not require urgent surgical treatment.
- Candidate for surgical, ablative, and surveillance approach.
- Willingness to obtain more information to aid decision-making.
- Understanding and willingness to provide consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.